This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266.
Falini B, Nicoletti I, Martelli MF, Mecucci C . Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+AML): biologic and clinical features. Blood 2007; 109: 874–885.
Gattenlohner S, Peter C, Bonengel M, Einsele H, Bargou R, Muller-Hermelink HK et al. Detecting the JAK2 V617F mutation in fresh and ‘historic’ blood and bone marrow. Leukemia 2007; 21: 1599–1602.
Di Ianni M, Moretti L, Del Papa B, Gaozza E, Bell AS, Falzetti F et al. A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders. Leukemia 2006; 20: 1895–1897.
Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006; 108: 1999–2005.
Pasqualucci L, Liso A, Martelli MP, Bolli N, Pacini R, Tabarrini A et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood 2006; 108: 4146–4155.
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.
Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006; 108: 3548–3555.
Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375–379.
Illmer T, Schaich M, Ehninger G, Thiede C . Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias. Haematologica 2007; 92: 137–138.
Caudill JS, Sternberg AJ, Li CY, Tefferi A, Lasho TL, Steensma DP . C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. Br J Haematol 2006; 133: 638–641.
Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270–276.
Acknowledgements
This study was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) to BF and by grants 310000-108006/1 from the Swiss National Science Foundation and the Swiss Cancer League (OCS-01742-08-2005) to RCS. We are grateful to Dr GA Boyd for editorial assistance. BF has applied for a patent on the clinical use of NPM mutants.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Pasqualucci, L., Li, S., Meloni, G. et al. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?. Leukemia 22, 1459–1463 (2008). https://doi.org/10.1038/sj.leu.2405093
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2405093
This article is cited by
-
Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family
Leukemia (2009)
-
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia
Leukemia (2009)
-
Therapy-related acute myeloid leukaemia with mutated NPM1: treatment induced or de novo in origin?
Leukemia (2008)
-
BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features
Leukemia (2008)